$USPH
U S PHYSICAL THERAPY INC /NV Stock $usph

$usph Overview Financials Valuation SEC Filings Company Website

2019 Q4 Form 10-K Financial Statement

#000114036121006642 Filed on March 01, 2021

Income Statement

Concept	2019 Q4	2018 Q4	2018 Q2
Revenue	$122.1M	$117.3M	$115.1M
YoY Change	4.06%	7.46%	10.35%
Cost Of Revenue	$95.10M	$92.10M	$87.90M
YoY Change	3.26%	8.99%	10.29%
Gross Profit	$26.96M	$25.22M	$27.15M
YoY Change	6.9%	2.1%	10.38%
Gross Profit Margin	22.08%	21.49%	23.59%
Selling, General & Admin	$11.70M	$10.40M	$10.13M
YoY Change	12.5%	1.96%	13.8%
% of Gross Profit	43.4%	41.24%	37.3%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization	$2.720M	$2.420M	$2.400M
YoY Change	12.4%	-0.82%	-1.23%
% of Gross Profit	10.09%	9.6%	8.84%
Operating Expenses	$11.70M	$10.50M	$10.13M
YoY Change	11.43%	3.96%	13.8%
Operating Profit	$15.29M	$14.80M	$17.03M
YoY Change	3.26%	1.4%	8.45%
Interest Expense	-$800.0K	-$300.0K	$545.0K
YoY Change	166.67%	-95.89%	-108.79%
% of Operating Profit	-5.23%	-2.03%	3.2%
Other Income/Expense, Net
YoY Change
Pretax Income	$14.40M	$16.30M	$16.50M
YoY Change	-11.66%	143.28%	73.72%
Income Tax	$2.400M	$2.600M	$3.267M
% Of Pretax Income	16.67%	15.95%	19.8%
Net Earnings	$7.900M	$10.40M	$9.246M
YoY Change	-24.04%	42.47%	88.69%
Net Earnings / Revenue	6.47%	8.86%	8.03%
Basic Earnings Per Share
Diluted Earnings Per Share	$617.2K	$818.9K	$724.4K
COMMON SHARES
Basic Shares Outstanding	12.77M
Diluted Shares Outstanding

Balance Sheet

Concept	2019 Q4	2018 Q4	2018 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$23.50M	$23.40M	$27.10M
YoY Change	0.43%	6.85%	34.16%
Cash & Equivalents	$23.55M	$23.37M	$27.15M
Short-Term Investments
Other Short-Term Assets	$5.787M	$4.353M	$5.200M
YoY Change	32.94%	-9.31%	-24.64%
Inventory
Prepaid Expenses
Receivables	$46.23M	$44.75M	$54.00M
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$85.39M	$79.21M	$86.40M
YoY Change	7.79%	2.74%	8.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$22.09M	$20.17M	$19.70M
YoY Change	9.52%	-1.13%	-2.48%
Goodwill	$317.7M	$293.5M
YoY Change	8.23%	8.18%
Intangibles	$52.59M	$48.83M
YoY Change	7.7%
Long-Term Investments
YoY Change
Other Assets	$1.519M	$1.430M	$1.400M
YoY Change	6.22%	19.17%	7.69%
Total Long-Term Assets	$545.1M	$364.0M	$354.1M
YoY Change	49.78%	6.45%	4.86%
TOTAL ASSETS
Total Short-Term Assets	$85.39M	$79.21M	$86.40M
Total Long-Term Assets	$545.1M	$364.0M	$354.1M
Total Assets	$630.5M	$443.2M	$440.5M
YoY Change	42.27%	5.77%	5.56%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.500M	$2.000M	$1.700M
YoY Change	25.0%	-9.09%	6.25%
Accrued Expenses	$30.86M	$38.49M	$35.40M
YoY Change	-19.84%	26.21%	23.34%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change
Long-Term Debt Due	$728.0K	$1.434M	$4.800M
YoY Change	-49.23%	-64.15%	108.7%
Total Short-Term Liabilities	$60.56M	$41.95M	$41.90M
YoY Change	44.38%	5.92%	19.03%
LONG-TERM LIABILITIES
Long-Term Debt	$50.36M	$38.40M	$56.60M
YoY Change	31.14%	-32.27%	-22.89%
Other Long-Term Liabilities	$141.0K	$829.0K	$2.700M
YoY Change	-82.99%	-71.41%	50.0%
Total Long-Term Liabilities	$50.50M	$39.23M	$59.30M
YoY Change	28.73%	-34.18%	-21.14%
TOTAL LIABILITIES
Total Short-Term Liabilities	$60.56M	$41.95M	$41.90M
Total Long-Term Liabilities	$50.50M	$39.23M	$59.30M
Total Liabilities	$181.4M	$92.35M	$228.9M
YoY Change	96.42%	-56.87%	2.88%
SHAREHOLDERS EQUITY
Retained Earnings	$184.4M	$167.4M
YoY Change	10.13%
Common Stock	$150.0K	$149.0K
YoY Change	0.67%
Preferred Stock
YoY Change
Treasury Stock (at cost)	$31.63M	$31.63M
YoY Change	0.0%
Treasury Stock Shares	$2.215M	$2.215M
Shareholders Equity	$240.3M	$215.9M	$211.6M
YoY Change
Total Liabilities & Shareholders Equity	$560.8M	$443.2M	$440.5M
YoY Change	26.55%	5.77%	5.56%

Cashflow Statement

Concept	2019 Q4	2018 Q4	2018 Q2
OPERATING ACTIVITIES
Net Income	$7.900M	$10.40M	$9.246M
YoY Change	-24.04%	42.47%	88.69%
Depreciation, Depletion And Amortization	$2.720M	$2.420M	$2.400M
YoY Change	12.4%	-0.82%	-1.23%
Cash From Operating Activities	$15.99M	$19.00M	$15.09M
YoY Change	-15.84%	21.02%	88.15%
INVESTING ACTIVITIES
Capital Expenditures	-$2.760M	-$1.880M	-$1.870M
YoY Change	46.81%	23.68%	12.65%
Acquisitions			$16.37M
YoY Change
Other Investing Activities	-$3.260M	-$150.0K	-$8.350M
YoY Change	2073.33%	-94.66%	-53.59%
Cash From Investing Activities	-$6.020M	-$2.030M	-$10.22M
YoY Change	196.55%	-53.12%	-47.99%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-14.27M	-25.84M	2.470M
YoY Change	-44.78%	276.68%	-63.24%
NET CHANGE
Cash From Operating Activities	15.99M	19.00M	15.09M
Cash From Investing Activities	-6.020M	-2.030M	-10.22M
Cash From Financing Activities	-14.27M	-25.84M	2.470M
Net Change In Cash	-4.300M	-8.870M	7.340M
YoY Change	-51.52%	-296.67%	-249.49%
FREE CASH FLOW
Cash From Operating Activities	$15.99M	$19.00M	$15.09M
Capital Expenditures	-$2.760M	-$1.880M	-$1.870M
Free Cash Flow	$18.75M	$20.88M	$16.96M
YoY Change	-10.2%	21.25%	75.21%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value
CY2020	dei	Entity Registrant Name EntityRegistrantName	U S PHYSICAL THERAPY INC /NV
CY2020	dei	Entity Central Index Key EntityCentralIndexKey	0000885978
CY2020	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2020	dei	Amendment Flag AmendmentFlag	false
CY2020	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2020
CY2020	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2020	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	NV
CY2020	dei	Entity Address State Or Province EntityAddressStateOrProvince	TX
CY2020	usph	Employment Agreements Retirement Date EmploymentAgreementsRetirementDate	2021-08-31
CY2020	dei	Document Type DocumentType	10-K
CY2020	dei	Document Annual Report DocumentAnnualReport	true
CY2019	usph	Number Of Regions NumberOfRegions	6
CY2020	usph	Number Of Regions NumberOfRegions	6
CY2020	dei	Document Period End Date DocumentPeriodEndDate	2020-12-31
CY2020	dei	Document Transition Report DocumentTransitionReport	false
CY2020	dei	Entity File Number EntityFileNumber	1-11151
CY2020	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	76-0364866
CY2020	dei	Entity Address Address Line1 EntityAddressAddressLine1	1300 WEST SAM HOUSTON PARKWAY SOUTH
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	69081000
CY2019Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	66099000
CY2020	dei	Entity Address Address Line2 EntityAddressAddressLine2	SUITE 300
CY2020	dei	Entity Address City Or Town EntityAddressCityOrTown	HOUSTON
CY2020	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	77042
CY2020	dei	City Area Code CityAreaCode	713
CY2020	dei	Local Phone Number LocalPhoneNumber	297-7000
CY2020	dei	Security12b Title Security12bTitle	Common Stock, $.01 par value
CY2020	dei	Trading Symbol TradingSymbol	USPH
CY2020	dei	Security Exchange Name SecurityExchangeName	NYSE
CY2020	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2020	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2020	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2020	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2020	dei	Entity Filer Category EntityFilerCategory	Large Accelerated Filer
CY2020	dei	Entity Small Business EntitySmallBusiness	false
CY2020	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2020	dei	Entity Shell Company EntityShellCompany	false
CY2020Q2	dei	Entity Public Float EntityPublicFloat	565300000
CY2021Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	12897096
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	32918000
CY2019Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	23548000
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2008000
CY2019Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	2698000
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	41906000
CY2019Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	46228000
CY2020Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9039000
CY2019Q4	us-gaap	Accounts And Other Receivables Net Current AccountsAndOtherReceivablesNetCurrent	9823000
CY2020Q4	us-gaap	Other Assets Current OtherAssetsCurrent	3773000
CY2019Q4	us-gaap	Other Assets Current OtherAssetsCurrent	5787000
CY2020Q4	us-gaap	Assets Current AssetsCurrent	87636000
CY2019Q4	us-gaap	Assets Current AssetsCurrent	85386000
CY2020Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	55426000
CY2019Q4	us-gaap	Furniture And Fixtures Gross FurnitureAndFixturesGross	54942000
CY2020Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	35320000
CY2019Q4	us-gaap	Leasehold Improvements Gross LeaseholdImprovementsGross	33247000
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	90746000
CY2019Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	88189000
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21665000
CY2019Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	22090000
CY2020Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	81595000
CY2019Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	81586000
CY2020Q4	us-gaap	Goodwill Goodwill	345646000
CY2019Q4	us-gaap	Goodwill Goodwill	317676000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56280000
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	52588000
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1539000
CY2019Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	1519000
CY2020Q4	us-gaap	Assets Assets	594361000
CY2019Q4	us-gaap	Assets Assets	560845000
CY2020Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1335000
CY2019Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2494000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59746000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30855000
CY2020Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	27512000
CY2019Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	26486000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4899000
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	728000
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	93492000
CY2019Q4	us-gaap	Liabilities Current LiabilitiesCurrent	60563000
CY2020Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	596000
CY2019Q4	us-gaap	Long Term Notes Payable LongTermNotesPayable	4361000
CY2020Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	16000000
CY2019Q4	us-gaap	Long Term Line Of Credit LongTermLineOfCredit	46000000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	7779000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	10071000
CY2020Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	61985000
CY2019Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	60258000
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	4539000
CY2019Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	141000
CY2020Q4	us-gaap	Liabilities Liabilities	184391000
CY2019Q4	us-gaap	Liabilities Liabilities	181394000
CY2020Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	132340000
CY2019Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	137750000
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies
CY2019Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000
CY2019Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	500000
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2019Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2019Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2019Q4	us-gaap	Preferred Stock Value PreferredStockValue	0
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2019Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	20000000
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	95622000
CY2019Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87383000
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	212015000
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	15066282
CY2019Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	14989337
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	151000
CY2019Q4	us-gaap	Common Stock Value CommonStockValue	150000
CY2019	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	45049000
CY2019Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	184352000
CY2020Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2214737
CY2019Q4	us-gaap	Treasury Stock Shares TreasuryStockShares	2214737
CY2020Q4	us-gaap	Treasury Stock Value TreasuryStockValue	31628000
CY2019Q4	us-gaap	Treasury Stock Value TreasuryStockValue	31628000
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	276160000
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	240257000
CY2020Q4	us-gaap	Minority Interest MinorityInterest	1470000
CY2019Q4	us-gaap	Minority Interest MinorityInterest	1444000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	277630000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	241701000
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	594361000
CY2019Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	560845000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	422969000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	481969000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	453911000
CY2020	us-gaap	Labor And Related Expense LaborAndRelatedExpense	235629000
CY2019	us-gaap	Labor And Related Expense LaborAndRelatedExpense	274233000
CY2018	us-gaap	Labor And Related Expense LaborAndRelatedExpense	259228000
CY2020	usph	Rent Supplies Contract Labor And Other RentSuppliesContractLaborAndOther	84336000
CY2019	usph	Rent Supplies Contract Labor And Other RentSuppliesContractLaborAndOther	90379000
CY2018	usph	Rent Supplies Contract Labor And Other RentSuppliesContractLaborAndOther	88426000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4623000
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4858000
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4603000
CY2020	us-gaap	Restructuring Charges RestructuringCharges	2072000
CY2019	us-gaap	Restructuring Charges RestructuringCharges	25000
CY2018	us-gaap	Restructuring Charges RestructuringCharges	-9000
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1859000
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Costs And Expenses CostsAndExpenses	328519000
CY2019	us-gaap	Costs And Expenses CostsAndExpenses	369495000
CY2018	us-gaap	Costs And Expenses CostsAndExpenses	352248000
CY2020	us-gaap	Gross Profit GrossProfit	94450000
CY2019	us-gaap	Gross Profit GrossProfit	112474000
CY2018	us-gaap	Gross Profit GrossProfit	101663000
CY2020	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	42037000
CY2018	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	41349000
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	52413000
CY2019	us-gaap	Operating Income Loss OperatingIncomeLoss	67425000
CY2018	us-gaap	Operating Income Loss OperatingIncomeLoss	60314000
CY2020	usph	Relief Funds ReliefFunds	13501000
CY2019	usph	Relief Funds ReliefFunds	0
CY2018	usph	Relief Funds ReliefFunds	0
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11369000
CY2020	us-gaap	Gain Loss On Sale Of Interest In Projects GainLossOnSaleOfInterestInProjects	1091000
CY2019	us-gaap	Gain Loss On Sale Of Interest In Projects GainLossOnSaleOfInterestInProjects	5514000
CY2018	us-gaap	Gain Loss On Sale Of Interest In Projects GainLossOnSaleOfInterestInProjects	0
CY2020	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2019	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	0
CY2018	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	1846000
CY2020	us-gaap	Interest And Other Income InterestAndOtherIncome	142000
CY2019	us-gaap	Interest And Other Income InterestAndOtherIncome	46000
CY2018	us-gaap	Interest And Other Income InterestAndOtherIncome	93000
CY2020	usph	Interest Expense Debt And Other InterestExpenseDebtAndOther	1634000
CY2019	usph	Interest Expense Debt And Other InterestExpenseDebtAndOther	2079000
CY2018	usph	Interest Expense Debt And Other InterestExpenseDebtAndOther	2042000
CY2020	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	13100000
CY2019	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	3481000
CY2018	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-103000
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	65513000
CY2019	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	70906000
CY2018	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	60211000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13022000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13647000
CY2020	us-gaap	Profit Loss ProfitLoss	52491000
CY2019	us-gaap	Profit Loss ProfitLoss	57259000
CY2018	us-gaap	Profit Loss ProfitLoss	48842000
CY2020	usph	Net Income Loss Attributable To Noncontrolling Interest Permanent Equity NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity	6122000
CY2019	usph	Net Income Loss Attributable To Noncontrolling Interest Permanent Equity NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity	6561000
CY2018	usph	Net Income Loss Attributable To Noncontrolling Interest Permanent Equity NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity	5536000
CY2020	usph	Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity	11175000
CY2018	usph	Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity	8433000
CY2020	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	17297000
CY2020	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	7917000
CY2020	usph	Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans	486000
CY2019	usph	Net Income Loss Attributable To Redeemable Noncontrolling Interest Temporary Equity NetIncomeLossAttributableToRedeemableNoncontrollingInterestTemporaryEquity	10659000
CY2019	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	17220000
CY2018	us-gaap	Net Income Loss Attributable To Noncontrolling Interest NetIncomeLossAttributableToNoncontrollingInterest	13969000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	35194000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	40039000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	34873000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	2.48
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	2.45
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	1.31
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12835000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12756000
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12666000
CY2020	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.32
CY2019	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	1.14
CY2018	us-gaap	Common Stock Dividends Per Share Declared CommonStockDividendsPerShareDeclared	0.92
CY2017Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	206070000
CY2018	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000
CY2018	usph	Revaluation Of Redeemable Non Controlling Interest Net Of Tax RevaluationOfRedeemableNonControllingInterestNetOfTax	-18268000
CY2018	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	5939000
CY2018	usph	Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans	373000
CY2018	usph	Sale Of Non Controlling Interest Net Of Tax And Purchases SaleOfNonControllingInterestNetOfTaxAndPurchases	-272000
CY2018	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	11664000
CY2018	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	5812000
CY2018	us-gaap	Stockholders Equity Other StockholdersEquityOther	99000
CY2018	usph	Net Income Loss Attributable To Noncontrolling Interest Permanent Equity NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity	5536000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	34873000
CY2018Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	216875000
CY2019	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000
CY2019	usph	Revaluation Of Redeemable Non Controlling Interest Net Of Tax RevaluationOfRedeemableNonControllingInterestNetOfTax	-8771000
CY2019	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	6985000
CY2019	usph	Transfer Of Compensation Liability For Certain Stock Issued Pursuant To Incentive Plans TransferOfCompensationLiabilityForCertainStockIssuedPursuantToIncentivePlans	636000
CY2019	usph	Purchase Of Partnership Interests Redeemable Non Controlling Interests PurchaseOfPartnershipInterestsRedeemableNonControllingInterests	-292000
CY2019	usph	Sale Of Non Controlling Interest Net Of Tax And Purchases SaleOfNonControllingInterestNetOfTaxAndPurchases	196000
CY2019	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	14555000
CY2019	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	6014000
CY2019	us-gaap	Stockholders Equity Other StockholdersEquityOther	40000
CY2019	usph	Net Income Loss Attributable To Noncontrolling Interest Permanent Equity NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity	6561000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	40039000
CY2019Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	241701000
CY2020	us-gaap	Stock Issued During Period Value Restricted Stock Award Net Of Forfeitures StockIssuedDuringPeriodValueRestrictedStockAwardNetOfForfeitures	1000
CY2020	usph	Revaluation Of Redeemable Non Controlling Interest Net Of Tax RevaluationOfRedeemableNonControllingInterestNetOfTax	-3415000
CY2020	usph	Purchase Of Partnership Interests Redeemable Non Controlling Interests PurchaseOfPartnershipInterestsRedeemableNonControllingInterests	-168000
CY2020	usph	Sale Of Non Controlling Interest Net Of Tax And Purchases SaleOfNonControllingInterestNetOfTaxAndPurchases	-164000
CY2020	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	4110000
CY2020	us-gaap	Minority Interest Decrease From Distributions To Noncontrolling Interest Holders MinorityInterestDecreaseFromDistributionsToNoncontrollingInterestHolders	5928000
CY2020	us-gaap	Stockholders Equity Other StockholdersEquityOther	-6000
CY2020	usph	Net Income Loss Attributable To Noncontrolling Interest Permanent Equity NetIncomeLossAttributableToNoncontrollingInterestPermanentEquity	6122000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	35194000
CY2020Q4	us-gaap	Stockholders Equity Including Portion Attributable To Noncontrolling Interest StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest	277630000
CY2020	us-gaap	Profit Loss ProfitLoss	52491000
CY2019	us-gaap	Profit Loss ProfitLoss	57259000
CY2018	us-gaap	Profit Loss ProfitLoss	48842000
CY2020	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10533000
CY2019	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	10095000
CY2018	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9755000
CY2020	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4623000
CY2018	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-345000
CY2019	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4858000
CY2018	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	4603000
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	7917000
CY2019	us-gaap	Share Based Compensation ShareBasedCompensation	6985000
CY2018	us-gaap	Share Based Compensation ShareBasedCompensation	5939000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-258000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4651000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4813000
CY2020	usph	Gain On Sale Of Partnership Interest Net Of Tax GainOnSaleOfPartnershipInterestNetOfTax	1091000
CY2019	usph	Gain On Sale Of Partnership Interest Net Of Tax GainOnSaleOfPartnershipInterestNetOfTax	5514000
CY2018	usph	Gain On Sale Of Partnership Interest Net Of Tax GainOnSaleOfPartnershipInterestNetOfTax	1846000
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1859000
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2018	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	281000
CY2019	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	96000
CY2018	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	167000
CY2020	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-899000
CY2019	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	6376000
CY2018	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	3434000
CY2020	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	-1661000
CY2019	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	2499000
CY2018	us-gaap	Increase Decrease In Accounts Receivable And Other Operating Assets IncreaseDecreaseInAccountsReceivableAndOtherOperatingAssets	1087000
CY2020	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	-4161000
CY2019	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	1878000
CY2020	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	12427000
CY2019	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-4209000
CY2018	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	4876000
CY2020	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	4492000
CY2019	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	-1020000
CY2018	us-gaap	Increase Decrease In Other Noncurrent Liabilities IncreaseDecreaseInOtherNoncurrentLiabilities	32000
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	99995000
CY2019	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	62448000
CY2018	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	73005000
CY2020	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	7639000
CY2019	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	10189000
CY2018	us-gaap	Payments To Acquire Productive Assets PaymentsToAcquireProductiveAssets	7193000
CY2020	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	23907000
CY2019	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	30597000
CY2018	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	16367000
CY2020	usph	Payments To Acquire Redeemable Non Controlling Interest PaymentsToAcquireRedeemableNonControllingInterest	20385000
CY2019	usph	Payments To Acquire Redeemable Non Controlling Interest PaymentsToAcquireRedeemableNonControllingInterest	8651000
CY2018	usph	Payments To Acquire Redeemable Non Controlling Interest PaymentsToAcquireRedeemableNonControllingInterest	0
CY2020	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	238000
CY2019	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	428000
CY2018	us-gaap	Payments To Acquire Interest In Subsidiaries And Affiliates PaymentsToAcquireInterestInSubsidiariesAndAffiliates	350000
CY2020	us-gaap	Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates	127000
CY2019	us-gaap	Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates	207000
CY2018	us-gaap	Proceeds From Divestiture Of Interest In Subsidiaries And Affiliates ProceedsFromDivestitureOfInterestInSubsidiariesAndAffiliates	0
CY2020	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	839000
CY2019	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	11665000
CY2018	us-gaap	Proceeds From Divestiture Of Businesses ProceedsFromDivestitureOfBusinesses	1000
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-51203000
CY2019	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-37993000
CY2018	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-23909000
CY2020	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	18331000
CY2019	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	16235000
CY2018	us-gaap	Payments Of Dividends Minority Interest PaymentsOfDividendsMinorityInterest	15646000
CY2020	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	4110000
CY2019	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	14555000
CY2018	us-gaap	Payments Of Dividends Common Stock PaymentsOfDividendsCommonStock	11664000
CY2020	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	214000000
CY2019	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	145000000
CY2018	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	103000000
CY2020	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	244000000
CY2019	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	137000000
CY2018	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	119000000
CY2020	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	0
CY2019	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	0
CY2018	us-gaap	Payments For Repurchase Of Redeemable Noncontrolling Interest PaymentsForRepurchaseOfRedeemableNoncontrollingInterest	265000
CY2020	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1037000
CY2019	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	1433000
CY2018	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	4044000
CY2020	usph	Medicare Accelerated And Advance Payment Funds MedicareAcceleratedAndAdvancePaymentFunds	14054000
CY2019	usph	Medicare Accelerated And Advance Payment Funds MedicareAcceleratedAndAdvancePaymentFunds	0
CY2018	usph	Medicare Accelerated And Advance Payment Funds MedicareAcceleratedAndAdvancePaymentFunds	0
CY2020	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	2000
CY2019	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-52000
CY2018	us-gaap	Proceeds From Payments For Other Financing Activities ProceedsFromPaymentsForOtherFinancingActivities	-42000
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-39422000
CY2019	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-24275000
CY2018	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-47661000
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	9370000
CY2020	usph	Combined Physical Therapy Speech Language Pathology Expenses CombinedPhysicalTherapySpeechLanguagePathologyExpenses	3700
CY2019	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	180000
CY2018	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1435000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23548000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23368000
CY2017Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	21933000
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	32918000
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23548000
CY2018Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	23368000
CY2020	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	7677000
CY2019	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9856000
CY2018	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	9183000
CY2020	us-gaap	Interest Paid Net InterestPaidNet	1202000
CY2019	us-gaap	Interest Paid Net InterestPaidNet	1890000
CY2018	us-gaap	Interest Paid Net InterestPaidNet	2357000
CY2020	usph	Purchase Of Business Seller Financing Portion PurchaseOfBusinessSellerFinancingPortion	1121000
CY2019	usph	Purchase Of Business Seller Financing Portion PurchaseOfBusinessSellerFinancingPortion	4300000
CY2018	usph	Purchase Of Business Seller Financing Portion PurchaseOfBusinessSellerFinancingPortion	950000
CY2020	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0
CY2019	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	502000
CY2018	us-gaap	Noncash Or Part Noncash Acquisition Payables Assumed1 NoncashOrPartNoncashAcquisitionPayablesAssumed1	0
CY2020Q4	usph	Notes Payable Related To Purchase Of Redeemable Non Controlling Interest Temporary Equity NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterestTemporaryEquity	136000
CY2019Q4	usph	Notes Payable Related To Purchase Of Redeemable Non Controlling Interest Temporary Equity NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterestTemporaryEquity	283000
CY2018Q4	usph	Notes Payable Related To Purchase Of Redeemable Non Controlling Interest Temporary Equity NotesPayableRelatedToPurchaseOfRedeemableNonControllingInterestTemporaryEquity	0
CY2020Q4	usph	Notes Payable Related To Purchase Of Non Controlling Interest Permanent Equity NotesPayableRelatedToPurchaseOfNonControllingInterestPermanentEquity	699000
CY2019Q4	usph	Notes Payable Related To Purchase Of Non Controlling Interest Permanent Equity NotesPayableRelatedToPurchaseOfNonControllingInterestPermanentEquity	103000
CY2018Q4	usph	Notes Payable Related To Purchase Of Non Controlling Interest Permanent Equity NotesPayableRelatedToPurchaseOfNonControllingInterestPermanentEquity	0
CY2020	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0
CY2019	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	2870000
CY2018	us-gaap	Proceeds From Minority Shareholders ProceedsFromMinorityShareholders	0
CY2020	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	994000
CY2019	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	0
CY2018	us-gaap	Noncash Or Part Noncash Divestiture Amount Of Consideration Received1 NoncashOrPartNoncashDivestitureAmountOfConsiderationReceived1	0
CY2020	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	2
CY2020	usph	Percentage Of General Partnership Interest Owned PercentageOfGeneralPartnershipInterestOwned	0.01
CY2020Q4	usph	Number Of Clinics Operated NumberOfClinicsOperated	554
CY2020Q4	us-gaap	Number Of States In Which Entity Operates NumberOfStatesInWhichEntityOperates	39
CY2020	usph	Number Of Third Party Facilities NumberOfThirdPartyFacilities	38
CY2018Q3	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	5
CY2020Q4	usph	Number Of Closed Clinics Sold NumberOfClosedClinicsSold	14
CY2020	usph	Aggregate Sale Price Of Cinics AggregateSalePriceOfCinics	1100000
CY2020Q4	usph	Cash Received Related To Sale Of Clinics CashReceivedRelatedToSaleOfClinics	700000
CY2020Q4	usph	Note Receivable Related To Sale Of Clinics NoteReceivableRelatedToSaleOfClinics	400000
CY2020	usph	Number Of Installments For Note Receivable In Sale Consideration NumberOfInstallmentsForNoteReceivableInSaleConsideration	2
CY2020Q1	usph	Average Physical Therapy Patients Volumes Per Day Per Clinic AveragePhysicalTherapyPatientsVolumesPerDayPerClinic	26.2
CY2019	us-gaap	Number Of Businesses Acquired NumberOfBusinessesAcquired	1
CY2019	usph	Number Of Clinics Operates As A Satellite Clinic With Existing Partnerships NumberOfClinicsOperatesAsASatelliteClinicWithExistingPartnerships	1
CY2020Q2	usph	Average Physical Therapy Patients Volumes Per Day Per Clinic AveragePhysicalTherapyPatientsVolumesPerDayPerClinic	18.9
CY2020Q3	usph	Average Physical Therapy Patients Volumes Per Day Per Clinic AveragePhysicalTherapyPatientsVolumesPerDayPerClinic	25.8
CY2020Q4	usph	Average Physical Therapy Patients Volumes Per Day Per Clinic AveragePhysicalTherapyPatientsVolumesPerDayPerClinic	27.7
CY2020Q1	usph	Percentage Of Employees Furloughed Or Terminated PercentageOfEmployeesFurloughedOrTerminated	0.40
CY2020Q1	dei	Entity Number Of Employees EntityNumberOfEmployees	5500
CY2020Q2	usph	Number Of Furloughed Employees Returned NumberOfFurloughedEmployeesReturned	1200
CY2020	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	2
CY2018	usph	Number Of Regions NumberOfRegions	6
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1900000
CY2020	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	422969000
CY2019	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	481969000
CY2018	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	453911000
CY2020Q4	usph	Estimated Percentage Of Decrease In Payment EstimatedPercentageOfDecreaseInPayment	0.09
CY2020Q4	usph	Estimated Percentage Of Decrease In Payment EstimatedPercentageOfDecreaseInPayment	0.09
CY2020	usph	Estimated Percentage Of Decrease In Payment EstimatedPercentageOfDecreaseInPayment	0.035
CY2020	usph	Period Of Federal Debt Ceiling In Connection With Deficit Reductions PeriodOfFederalDebtCeilingInConnectionWithDeficitReductions	P10Y
CY2020	usph	Amount Of Reductions In Federal Spending AmountOfReductionsInFederalSpending	1200000000000
CY2020	usph	Reduction In Medicare Spending Percentage ReductionInMedicareSpendingPercentage	0.02
CY2013Q2	usph	Expected Reduction In Medicare Spending Percentage ExpectedReductionInMedicareSpendingPercentage	0.02
CY2015Q4	usph	Expected Reduction In Medicare Spending Percentage ExpectedReductionInMedicareSpendingPercentage	0.02
CY2018Q1	usph	Expected Reduction In Medicare Spending Percentage ExpectedReductionInMedicareSpendingPercentage	0.02
CY2020Q4	usph	Expected Reduction In Medicare Spending Percentage ExpectedReductionInMedicareSpendingPercentage	0.02
CY2020	usph	Combined Physical Therapy Speech Language Pathology Expenses CombinedPhysicalTherapySpeechLanguagePathologyExpenses	3700
CY2020	usph	Combined Physical Therapy Speech Language Pathology Expenses CombinedPhysicalTherapySpeechLanguagePathologyExpenses	3700
CY2020	usph	Combined Physical Therapy Speech Language Pathology Expenses CombinedPhysicalTherapySpeechLanguagePathologyExpenses	3700
CY2020	usph	Percentage Of Practice Expense Component Of Relative Value Unit PercentageOfPracticeExpenseComponentOfRelativeValueUnit	1
CY2020	usph	Percentage Reduction For Service In Office Or Other Non Institutional Settings PercentageReductionForServiceInOfficeOrOtherNonInstitutionalSettings	0.50
CY2020	usph	Reduction In Combined Physical Therapy Speech Language Pathology Expenses ReductionInCombinedPhysicalTherapySpeechLanguagePathologyExpenses	3000
CY2020	usph	Percentage Of Payment For Outpatient Therapy Services PercentageOfPaymentForOutpatientTherapyServices	0.85
CY2020	usph	Net Revenue From Medicare NetRevenueFromMedicare	101600000
CY2020	us-gaap	Financing Receivable Allowance For Credit Losses Policy For Uncollectible Amounts FinancingReceivableAllowanceForCreditLossesPolicyForUncollectibleAmounts	<div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Allowance for Credit Losses</div> <div><br/></div> <div style="display:none;"><br/></div> <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">The Company determines allowances for credit losses based on the specific agings and payor classifications at each clinic. The provision for credit losses is included in operating costs in the statements of net income. Patient accounts receivable, which are stated at the historical carrying amount net of contractual allowances, write-offs and allowance for credit losses, includes only those amounts the Company estimates to be collectible.</div>
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020	us-gaap	Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations	0
CY2018	us-gaap	Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations	0
CY2019	us-gaap	Interest Expense On Prepetition Liabilities Recognized In Statement Of Operations InterestExpenseOnPrepetitionLiabilitiesRecognizedInStatementOfOperations	0
CY2020	us-gaap	Use Of Estimates UseOfEstimates	<div style="text-align: left; color: #000000; font-family: 'Times New Roman'; font-size: 10pt; font-style: italic; font-weight: bold;">Use of Estimates</div> <div><br/></div> <div style="display:none;"><br/></div> <div style="text-align: left; text-indent: 36pt; color: #000000; font-family: 'Times New Roman'; font-size: 10pt;">In preparing the Company’s consolidated financial statements, management makes certain estimates and assumptions, especially in relation to, but not limited to, goodwill impairment, tradenames, allocations of purchase price, allowance for receivables, tax provision and contractual allowances, that affect the amounts reported in the consolidated financial statements and related disclosures. Actual results may differ from these estimates.</div>
CY2018Q2	usph	Business Combination Acquisition Fair Value Of Redeemable Non Controlling Interests BusinessCombinationAcquisitionFairValueOfRedeemableNonControllingInterests	8145000
CY2018Q2	usph	Payments To Acquire Businesses Consideration PaymentsToAcquireBusinessesConsideration	17317000
CY2018Q2	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	372000
CY2018Q2	us-gaap	Payments To Acquire Businesses Net Of Cash Acquired PaymentsToAcquireBusinessesNetOfCashAcquired	16367000
CY2018Q2	usph	Business Acquisition Cost Of Acquired Entity Debt Issued BusinessAcquisitionCostOfAcquiredEntityDebtIssued	950000
CY2018Q2	usph	Payments To Acquire Businesses Consideration PaymentsToAcquireBusinessesConsideration	17317000
CY2018Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Current Assets Receivables BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedCurrentAssetsReceivables	1633000
CY2018Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Noncurrent Assets BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNoncurrentAssets	305000
CY2018Q2	us-gaap	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Net BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNet	-525000
CY2019	us-gaap	Cash Acquired From Acquisition CashAcquiredFromAcquisition	890000
CY2018Q2	usph	Business Acquisition Purchase Price Allocation Net Tangible Asset BusinessAcquisitionPurchasePriceAllocationNetTangibleAsset	1413000
CY2018Q2	usph	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Referral Relationships BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedReferralRelationships	2926000
CY2018Q2	usph	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Non Competition Agreements BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedNonCompetitionAgreements	298000
CY2018Q2	usph	Business Combination Recognized Identifiable Assets Acquired And Liabilities Assumed Tradename BusinessCombinationRecognizedIdentifiableAssetsAcquiredAndLiabilitiesAssumedTradename	990000
CY2018Q2	us-gaap	Business Acquisition Purchase Price Allocation Goodwill Expected Tax Deductible Amount BusinessAcquisitionPurchasePriceAllocationGoodwillExpectedTaxDeductibleAmount	19835000
CY2020	usph	Number Of Partnership In Which Interest Acquired NumberOfPartnershipInWhichInterestAcquired	5
CY2020	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Purchase Of Interest By Parent ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesPurchaseOfInterestByParent	300000
CY2020	us-gaap	Consolidation Less Than Wholly Owned Subsidiary Parent Ownership Interest Changes Sale Of Interest By Parent ConsolidationLessThanWhollyOwnedSubsidiaryParentOwnershipInterestChangesSaleOfInterestByParent	100000
CY2020Q4	usph	Number Of Closed Clinics Sold NumberOfClosedClinicsSold	14
CY2020	usph	Aggregate Sale Price Of Cinics AggregateSalePriceOfCinics	1100000
CY2020Q4	usph	Cash Received Related To Sale Of Clinics CashReceivedRelatedToSaleOfClinics	700000
CY2020Q4	usph	Note Receivable Related To Sale Of Clinics NoteReceivableRelatedToSaleOfClinics	400000
CY2020	usph	Number Of Installments For Note Receivable In Sale Consideration NumberOfInstallmentsForNoteReceivableInSaleConsideration	2
CY2019	usph	Number Of Partnership In Which Interest Acquired NumberOfPartnershipInWhichInterestAcquired	4
CY2019	usph	Sale Of Noncontrolling Interest Percentage In Partnership One SaleOfNoncontrollingInterestPercentageInPartnershipOne	0.01
CY2019	usph	Tax Effect On Sale Of Noncontrolling Interest TaxEffectOnSaleOfNoncontrollingInterest	196000
CY2019Q4	us-gaap	Goodwill Goodwill	317676000
CY2018Q4	us-gaap	Goodwill Goodwill	293525000
CY2020	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	28540000
CY2019	us-gaap	Goodwill Acquired During Period GoodwillAcquiredDuringPeriod	31330000
CY2020	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	0
CY2019	us-gaap	Goodwill Written Off Related To Sale Of Business Unit GoodwillWrittenOffRelatedToSaleOfBusinessUnit	7325000
CY2020	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	1859000
CY2019	us-gaap	Goodwill Impairment Loss GoodwillImpairmentLoss	0
CY2020	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	1289000
CY2019	us-gaap	Goodwill Purchase Accounting Adjustments GoodwillPurchaseAccountingAdjustments	146000
CY2020Q4	us-gaap	Goodwill Goodwill	345646000
CY2019Q4	us-gaap	Goodwill Goodwill	317676000
CY2020Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	56280000
CY2019Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	52588000
CY2020	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3414000
CY2019	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	3015000
CY2018	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	2777000
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	24646000
CY2019Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	19340000
CY2020Q4	usph	Patients And Payors Related Liability PatientsAndPayorsRelatedLiability	5756000
CY2019Q4	usph	Patients And Payors Related Liability PatientsAndPayorsRelatedLiability	4303000
CY2020Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	2113000
CY2019Q4	us-gaap	Accrued Insurance Current AccruedInsuranceCurrent	2277000
CY2020Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	1333000
CY2019Q4	us-gaap	Liabilities Of Disposal Group Including Discontinued Operation Current LiabilitiesOfDisposalGroupIncludingDiscontinuedOperationCurrent	116000
CY2020Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	5715000
CY2019Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	0
CY2020Q4	usph	Medicare Accelerated And Advance Payments Program Funds Payable MedicareAcceleratedAndAdvancePaymentsProgramFundsPayable	14054000
CY2019Q4	usph	Medicare Accelerated And Advance Payments Program Funds Payable MedicareAcceleratedAndAdvancePaymentsProgramFundsPayable	0
CY2020Q4	usph	Deferred Employer Payroll Taxes Caresact DeferredEmployerPayrollTaxesCARESACT	4170000
CY2019Q4	usph	Deferred Employer Payroll Taxes Caresact DeferredEmployerPayrollTaxesCARESACT	0
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1959000
CY2019Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	4819000
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	59746000
CY2019Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	30855000
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	21495000
CY2019Q4	us-gaap	Long Term Debt LongTermDebt	51089000
CY2020Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	4899000
CY2019Q4	us-gaap	Long Term Debt Current LongTermDebtCurrent	728000
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	16596000
CY2019Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	50361000
CY2020	us-gaap	Line Of Credit Facility Unused Capacity Commitment Fee Percentage LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage	0.003
CY2019	us-gaap	Operating Lease Cost OperatingLeaseCost	30225000
CY2020Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	89497000
CY2020	us-gaap	Operating Lease Cost OperatingLeaseCost	30710000
CY2020	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1454000
CY2019	us-gaap	Short Term Lease Cost ShortTermLeaseCost	1212000
CY2020	us-gaap	Variable Lease Cost VariableLeaseCost	5752000
CY2019	us-gaap	Variable Lease Cost VariableLeaseCost	6074000
CY2020	us-gaap	Lease Cost LeaseCost	37916000
CY2019	us-gaap	Lease Cost LeaseCost	37511000
CY2020	us-gaap	Operating Lease Payments OperatingLeasePayments	30307000
CY2019	us-gaap	Operating Lease Payments OperatingLeasePayments	30077000
CY2020	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	32710000
CY2019	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	113222000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	29819000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	23861000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	17787000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	11487000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due After Year Five LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive	12294000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	95248000
CY2020Q4	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	5751000
CY2020Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y18D
CY2019Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y18D
CY2020Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.031
CY2019Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.039
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1865000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefits	1964000
CY2020Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	396000
CY2019Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Reserves And Accruals Allowance For Doubtful Accounts DeferredTaxAssetsTaxDeferredExpenseReservesAndAccrualsAllowanceForDoubtfulAccounts	514000
CY2020Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	558000
CY2019Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	840000
CY2020Q4	usph	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	23819000
CY2019Q4	usph	Deferred Tax Assets Lease Obligations DeferredTaxAssetsLeaseObligations	21445000
CY2020Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	26638000
CY2019Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	24763000
CY2020Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	12650000
CY2019Q4	us-gaap	Deferred Tax Liabilities Property Plant And Equipment DeferredTaxLiabilitiesPropertyPlantAndEquipment	13195000
CY2020Q4	usph	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	21419000
CY2019Q4	usph	Deferred Tax Liabilities Operating Lease Right Of Use Assets DeferredTaxLiabilitiesOperatingLeaseRightOfUseAssets	21416000
CY2020Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	348000
CY2019Q4	us-gaap	Deferred Tax Liabilities Other DeferredTaxLiabilitiesOther	223000
CY2020Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	34417000
CY2019Q4	us-gaap	Deferred Income Tax Liabilities DeferredIncomeTaxLiabilities	34834000
CY2020Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	7779000
CY2019Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	10071000
CY2020Q4	usph	Deferred Tax Assets Related To Redeemable Non Controlling Interests And Acquisitions Of Non Controlling Interests DeferredTaxAssetsRelatedToRedeemableNonControllingInterestsAndAcquisitionsOfNonControllingInterests	1200000
CY2020	us-gaap	Income Tax Expense Benefit Continuing Operations Adjustment Of Deferred Tax Asset Liability IncomeTaxExpenseBenefitContinuingOperationsAdjustmentOfDeferredTaxAssetLiability	1400000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.039
CY2019	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	2059000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.038
CY2018	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1722000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation State And Local Income Taxes EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes	0.037
CY2020	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	99000
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	10125000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2019	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	11274000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2018	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	9710000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.210
CY2020	us-gaap	Income Tax Reconciliation State And Local Income Taxes IncomeTaxReconciliationStateAndLocalIncomeTaxes	1956000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	-0.000
CY2019	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	871000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.016
CY2018	us-gaap	Income Tax Reconciliation Deductions IncomeTaxReconciliationDeductions	806000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Deductions EffectiveIncomeTaxRateReconciliationDeductions	0.017
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1040000
CY2020	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.021
CY2019	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1185000
CY2019	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.022
CY2018	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	743000
CY2018	us-gaap	Effective Income Tax Rate Reconciliation Nondeductible Expense EffectiveIncomeTaxRateReconciliationNondeductibleExpense	0.016
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13022000
CY2020	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.270
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13647000
CY2019	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.254
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11369000
CY2018	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.246
CY2019	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	3730000
CY2018	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	3771000
CY2018	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	11369000
CY2019	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0
CY2020	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	-220000
CY2018	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0
CY2020	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	10506000
CY2019	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	6523000
CY2018	us-gaap	Current Federal Tax Expense Benefit CurrentFederalTaxExpenseBenefit	5357000
CY2020	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2774000
CY2019	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	2473000
CY2018	us-gaap	Current State And Local Tax Expense Benefit CurrentStateAndLocalTaxExpenseBenefit	1199000
CY2020	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	13280000
CY2019	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	8996000
CY2018	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit	6556000
CY2020	us-gaap	Deferred Federal Income Tax Expense Benefit DeferredFederalIncomeTaxExpenseBenefit	-38000
CY2019	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	921000
CY2018	us-gaap	Deferred State And Local Income Tax Expense Benefit DeferredStateAndLocalIncomeTaxExpenseBenefit	1042000
CY2020	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-258000
CY2019	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4651000
CY2018	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	4813000
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13022000
CY2019	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	13647000
CY2020	us-gaap	Unrecognized Tax Benefits Interest On Income Taxes Expense UnrecognizedTaxBenefitsInterestOnIncomeTaxesExpense	0
CY2020Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2018Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2019Q4	us-gaap	Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued	0
CY2020	us-gaap	Revenues Revenues	422969000
CY2019	us-gaap	Revenues Revenues	481969000
CY2018	us-gaap	Revenues Revenues	453911000
CY2020	us-gaap	Gross Profit GrossProfit	94450000
CY2019	us-gaap	Gross Profit GrossProfit	112474000
CY2018	us-gaap	Gross Profit GrossProfit	101663000
CY2020Q4	us-gaap	Assets Assets	594361000
CY2019Q4	us-gaap	Assets Assets	560845000
CY2018Q4	us-gaap	Assets Assets	443166000
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Authorized ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized	2700000
CY2020Q4	usph	Share Based Compensation Arrangement By Share Based Payment Award Restricted Stock Grants For The Cumulative Period ShareBasedCompensationArrangementByShareBasedPaymentAwardRestrictedStockGrantsForTheCumulativePeriod	1523379
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	0
CY2020Q4	usph	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises For The Cumulative Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesForTheCumulativePeriod	918091
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	0
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Number Of Shares Available For Grant ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant	232535
CY2020Q4	usph	Share Based Compensation Arrangement By Share Based Payment Award For Shares Outstanding Restrictions Had Not Lapsed ShareBasedCompensationArrangementByShareBasedPaymentAwardForSharesOutstandingRestrictionsHadNotLapsed	127562
CY2019Q4	usph	Share Based Compensation Arrangement By Share Based Payment Award For Shares Outstanding Restrictions Had Not Lapsed ShareBasedCompensationArrangementByShareBasedPaymentAwardForSharesOutstandingRestrictionsHadNotLapsed	150771
CY2009Q1	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	859499
CY2020	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0
CY2019	us-gaap	Stock Repurchased During Period Shares StockRepurchasedDuringPeriodShares	0
CY2020	usph	Additional Estimated Repurchase Of Common Stock AdditionalEstimatedRepurchaseOfCommonStock	124740
CY2020Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	120.25
CY2020	usph	Defined Contribution Plan Period For New Employees Covered Under Plan DefinedContributionPlanPeriodForNewEmployeesCoveredUnderPlan	P3M
CY2020	us-gaap	Defined Contribution Plan Employer Matching Contribution Percent Of Match DefinedContributionPlanEmployerMatchingContributionPercentOfMatch	0.50
CY2018	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
CY2019	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
CY2020	us-gaap	Defined Contribution Plan Employer Discretionary Contribution Amount DefinedContributionPlanEmployerDiscretionaryContributionAmount	0
CY2020	usph	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	1900000
CY2019	usph	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	2000000.0
CY2018	usph	Defined Contribution Plan Employer Matching Contribution Amount DefinedContributionPlanEmployerMatchingContributionAmount	1800000
CY2020	usph	Employment Agreements Expiration Date EmploymentAgreementsExpirationDate	2021-12-31
CY2020	usph	Employment Agreements Expiration Date Two EmploymentAgreementsExpirationDateTwo	2022-02-28
CY2020	usph	Employment Agreements Expiration Date Three EmploymentAgreementsExpirationDateThree	2022-11-08
CY2020	usph	Renewal Period For Employment Agreement RenewalPeriodForEmploymentAgreement	P2Y
CY2020Q4	usph	Employee Compensation Future Payment Due Next Fiscal Year EmployeeCompensationFuturePaymentDueNextFiscalYear	37100000
CY2020Q4	usph	Employee Compensation Future Payment Due Next Fiscal Year Thereafter EmployeeCompensationFuturePaymentDueNextFiscalYearThereafter	6100000
CY2018	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	1.31
CY2020	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12835000
CY2019	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12756000
CY2020	us-gaap	Net Income Loss NetIncomeLoss	35194000
CY2019	us-gaap	Net Income Loss NetIncomeLoss	40039000
CY2018	us-gaap	Net Income Loss NetIncomeLoss	34873000
CY2020	usph	Charges To Retained Earnings Revaluation Of Non Controlling Interests ChargesToRetainedEarningsRevaluationOfNonControllingInterests	-4632000
CY2019	usph	Charges To Retained Earnings Revaluation Of Non Controlling Interests ChargesToRetainedEarningsRevaluationOfNonControllingInterests	-11893000
CY2018	usph	Charges To Retained Earnings Revaluation Of Non Controlling Interests ChargesToRetainedEarningsRevaluationOfNonControllingInterests	-24770000
CY2020	usph	Effective Income Tax Rate Reconciliation At Federal And State Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalAndStateStatutoryIncomeTaxRate	0.2625
CY2020	usph	Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate	-1216000
CY2019	usph	Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate	-3121000
CY2018	usph	Income Tax Reconciliation Income Tax Expense Benefit At Federal And State Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalAndStateStatutoryIncomeTaxRate	-6502000
CY2020	usph	Income Loss From Operations After Revaluation Of Non Controlling Interests IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests	31778000
CY2019	usph	Income Loss From Operations After Revaluation Of Non Controlling Interests IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests	31267000
CY2018	usph	Income Loss From Operations After Revaluation Of Non Controlling Interests IncomeLossFromOperationsAfterRevaluationOfNonControllingInterests	16605000
CY2020	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	2.48
CY2019	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	2.45
CY2018	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	12666000

Files In Submission

Name	View Source	Status
0001140361-21-006642-index-headers.html	Edgar Link	pending
0001140361-21-006642-index.html	Edgar Link	pending
0001140361-21-006642.txt	Edgar Link	pending
0001140361-21-006642-xbrl.zip	Edgar Link	pending
brhc10020853_10k.htm	Edgar Link	pending
brhc10020853_10k_htm.xml	Edgar Link	completed
brhc10020853_ex21-1.htm	Edgar Link	pending
brhc10020853_ex23-1.htm	Edgar Link	pending
brhc10020853_ex31-1.htm	Edgar Link	pending
brhc10020853_ex31-2.htm	Edgar Link	pending
brhc10020853_ex31-3.htm	Edgar Link	pending
brhc10020853_ex32-1.htm	Edgar Link	pending
brhc10020853_ex4-1.htm	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image0.jpg	Edgar Link	pending
image00002.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
usph-20201231.xsd	Edgar Link	pending
usph-20201231_cal.xml	Edgar Link	unprocessable
usph-20201231_def.xml	Edgar Link	unprocessable
usph-20201231_lab.xml	Edgar Link	unprocessable
usph-20201231_pre.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$USPH
U S PHYSICAL THERAPY INC /NV Stock $usph

2019 Q4 Form 10-K Financial Statement

#000114036121006642 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USPH U S PHYSICAL THERAPY INC /NV Stock $usph

2019 Q4 Form 10-K Financial Statement

#000114036121006642 Filed on March 01, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$USPH
U S PHYSICAL THERAPY INC /NV Stock $usph